MED Share Price | Medifast, Inc. Stock Analysis & Recommendation

Q: What does Medifast, Inc. do?

Overview: Medifast, Inc. produces, distributes, and sells weight loss, weight management, and healthy living products within the Miscellaneous industry and operates in the micro-cap market.Financial Snapshot: Most recent Net Sales: 116 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) Market cap: USD 148.27 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.75 Return on Equity: -0.84% Price to Book: 0.70Contact Details: Address: 11445 Cronhill Dr, OWINGS MILLS MD: 21117-2270 Tel: 1 732 7640619 Fax: 1 410 5818070 Website: https://www.medifast1.com

Q: Is Medifast, Inc. overvalued or undervalued?

As of 7 August 2025, the valuation grade for Medifast, Inc. has moved from expensive to attractive, indicating a shift in perception regarding its valuation. The company appears to be undervalued, particularly given its Price to Book Value of 0.66 and an EV to EBIT ratio of 2.98, despite the challenges reflected in its negative earnings metrics. In comparison to its peers, Medifast's P/E ratio stands at 62.80, while Thoughtworks Holding, Inc. and Chegg, Inc. exhibit significantly lower P/E ratios of -25.45 and -22.62, respectively, highlighting the relative attractiveness of Medifast within this group. Additionally, the company has underperformed against the S&P 500, with a year-to-date return of -17.31% compared to the index's 12.22%, and a staggering -91.61% return over the past five years, suggesting that while the stock may be undervalued, it has faced significant headwinds in the market.

Q: Is Medifast, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Medifast, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish, suggesting some positive momentum. However, the daily moving averages indicate a mildly bearish stance, and the Bollinger Bands show a mixed signal with a bullish weekly and mildly bearish monthly outlook. The Dow Theory reflects a mildly bullish weekly trend but no trend on the monthly basis. In terms of performance, Medifast has underperformed the S&P 500 significantly over the longer term, with a year-to-date return of -17.31% compared to the S&P 500's 12.22%, and a 1-year return of -22.58% against the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by the daily moving averages and mixed signals from other indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

187.99 k

Shareholding (Sep 2025)

FII

9.96%

Held by 77 FIIs

DII

17.29%

Held by 75 DIIs

Promoter

0.16%

How big is Medifast, Inc.?

22-Jun-2025

As of Jun 18, Medifast, Inc. has a market capitalization of 148.27 million and reported net sales of 543.45 million with a net profit of -6.99 million over the latest four quarters. Shareholder's funds total 210.11 million, and total assets are 293.23 million.

View full answer

What does Medifast, Inc. do?

22-Jun-2025

Medifast, Inc. produces and sells weight loss and healthy living products, operating in the micro-cap market with a recent net sales of $116 million and a net profit of -$1 million. The company has a market cap of $148.27 million and does not pay dividends.

View full answer

Who are in the management team of Medifast, Inc.?

22-Jun-2025

As of March 2022, the management team of Medifast, Inc. includes Executive Chairman and CEO Daniel Chard, Lead Independent Director Jeffrey Brown, and Independent Directors Kevin Byrnes, Constance Hallquist, Michael Hoer, and Scott Schlackman. They are responsible for the company's strategic direction and governance.

View full answer

Is Medifast, Inc. overvalued or undervalued?

20-Sep-2025

As of August 7, 2025, Medifast, Inc. is considered undervalued with a valuation grade shift to attractive, despite negative earnings metrics and a year-to-date return of -17.31%, compared to the S&P 500's 12.22%, while its Price to Book Value is 0.66 and EV to EBIT ratio is 2.98, indicating relative attractiveness against peers with lower P/E ratios.

View full answer

Is Medifast, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Medifast, Inc. shows a mildly bearish technical trend, with daily moving averages indicating bearishness despite some positive momentum from weekly and monthly MACD indicators, and it has significantly underperformed the S&P 500 year-to-date and over the past year.

View full answer

Compare Medifast, Inc. with Similar Stocks

Montrose Environmental Group, Inc.Chegg, Inc.Thoughtworks Holding, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a fall in PBT of -258.16%, the company declared Very Negative results in Jun 25

The company has declared negative results for the last 12 consecutive quarters
NET PROFIT(HY) At USD 0.33 MM has Grown at -87.43%
OPERATING CASH FLOW(Y) Lowest at USD 4.15 MM
NET SALES(Q) Lowest at USD 105.56 MM

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 130 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.78

Return on Equity

-1.11%

Price to Book

0.60

Revenue and Profits:

Net Sales:

106 Million

(Quarterly Results - Jun 2025)

Net Profit:

2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.93%

6 Months

-48.81%

1 Year

-47.08%

2 Years

-85.99%

3 Years

-94.13%

4 Years

-96.16%

5 Years

-89.85%

Medifast, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-8.74%

EBIT Growth (5y)

-64.79%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.75

Sales to Capital Employed (avg)

3.88

Tax Ratio

3.78%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

184.68%

ROE (avg)

54.42%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.66

EV to EBIT

2.98

EV to EBITDA

-1.70

EV to Capital Employed

-0.36

EV to Sales

-0.03

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-0.84%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 55 Schemes (72.5%)

Foreign Institutions

Held by 77 Foreign Institutions (9.96%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -8.73% vs -2.77% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 412.50% vs -200.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105.60",
          "val2": "115.70",
          "chgp": "-8.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.00",
          "val2": "2.00",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.60",
          "val2": "0.60",
          "chgp": "333.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.50",
          "val2": "-0.80",
          "chgp": "412.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10.10%",
          "val2": "-10.90%",
          "chgp": "0.08%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -43.80% vs -32.94% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -97.89% vs -30.78% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "602.50",
          "val2": "1,072.10",
          "chgp": "-43.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "20.30",
          "val2": "144.10",
          "chgp": "-85.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.10",
          "val2": "99.40",
          "chgp": "-97.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "4.80%",
          "val2": "117.90%",
          "chgp": "-11.31%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

105.60

115.70

-8.73%

Operating Profit (PBDIT) excl Other Income

3.00

2.00

50.00%

Interest

0.00

Exceptional Items

2.60

0.60

333.33%

Consolidate Net Profit

2.50

-0.80

412.50%

Operating Profit Margin (Excl OI)

-10.10%

-10.90%

0.08%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -8.73% vs -2.77% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 412.50% vs -200.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

602.50

1,072.10

-43.80%

Operating Profit (PBDIT) excl Other Income

20.30

144.10

-85.91%

Interest

0.00

Exceptional Items

-4.10

0.00

Consolidate Net Profit

2.10

99.40

-97.89%

Operating Profit Margin (Excl OI)

4.80%

117.90%

-11.31%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -43.80% vs -32.94% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -97.89% vs -30.78% in Dec 2023

All Annual Results

Company CV

About Medifast, Inc.

Medifast, Inc.

Miscellaneous

Medifast, Inc. produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins. Its business units include Optavia, Medifast Direct, Franchise Medifast Weight Control Centers (MWCC) and Medifast Wholesale. Optavia is a personal coaching division of the Company that consists of Optavia Coaches, who provides coaching and support to clients utilizing the Optavia platform. Medifast Direct is its direct-to-consumer business unit that allows customers to order Medifast products directly through its Website or its in-house call center. The MWCC business unit sells product through franchise and reseller locations, which offers structured programs and a team of professionals to help customers achieve weight-loss and weight-management success at center locations.

Company Coordinates

Company Details

11445 Cronhill Dr , OWINGS MILLS MD : 21117-2270

Tel: 1 732 7640619

https://www.medifast1.com

Registrar Details

Medifast, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Medifast, Inc.?

Watch in Real-Time

What does Medifast, Inc. do?

Who are in the management team of Medifast, Inc.?

Is Medifast, Inc. overvalued or undervalued?

Is Medifast, Inc. technically bullish or bearish?

Compare Medifast, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

With a fall in PBT of -258.16%, the company declared Very Negative results in Jun 25

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Medifast, Inc.

Company Coordinates